Innoviva is no longer just a GSK royalty stub. It is a cash-rich Delaware holding company that is using Relvar, Breo, and Anoro checks to build a hospital infection and shock franchise, mark a concentrated bacteriophage bet, and buy its own stock. Chief Executive Officer Pavel Raifeld is asking holders to judge the firm on Innoviva Specialty Therapeutics growth and on capital deployment, not on whether the respiratory royalty still grows. The June quarter showed why that framing is incomplete. Product sales rose fast, operating income barely moved, and a mark-to-market collapse in Armata Pharmaceuticals flipped a profitable operator into a large GAAP loss.
Gross royalty receipts from Glaxo Group Limited were $59.8 million in the June quarter, down from the year-ago period and only a small step up from March. Net product sales were $51.8 million, with United States hospital products still led by Giapreza and Xacduro. License revenue jumped in the same quarter as the Dr. Reddy's Laboratories Xacduro pact. Income from operations was $50.9 million. Fair-value losses on equity-method and other long-term holdings totaled $161.0 million, almost all of it Armata. Cash still ended June at $570.4 million, and the company kept buying stock under the $125 million authorization.
The investment question is not whether the hospital line can grow. It is whether that growth, plus a second-half launch of Nuzolvence and a still-large GSK check, can replace royalty erosion and justify leaving hundreds of millions marked in Armata and other private healthcare names. Management says United States IST net product sales of at least $150 million are on track for the year. First-half United States product sales were only $70.8 million, so the second half has to do more work than the first. Holders own an operating company that still prints cash and an investment company whose marks dominate reported earnings.